# Master Plan Index & Implementation Summary

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Executive Director & Chief Operating Officer
**Purpose**: Comprehensive index of all 89 strategic documents for Mark Egly Foundation with implementation priorities, interdependencies, and execution roadmap

---

## üìã Table of Contents

1. [Master Plan Overview](#master-plan-overview)
2. [Document Index by Phase](#document-index-by-phase)
3. [Implementation Priorities](#implementation-priorities)
4. [Document Interdependencies](#document-interdependencies)
5. [5-Year Execution Timeline](#5-year-execution-timeline)
6. [Budget Summary](#budget-summary)
7. [Success Metrics Dashboard](#success-metrics-dashboard)
8. [Resource Requirements](#resource-requirements)
9. [Risk Matrix](#risk-matrix)
10. [Quick Start Guide](#quick-start-guide)

---

## Master Plan Overview

### The Vision

**Mission**: Increase Alpha-1 Antitrypsin Deficiency (AATD) diagnosis rate from 10% to 50%, accelerate research toward a cure, and improve lives of all AATD patients and families.

**Named in Honor**: Mark Egly‚Äîpassionate AATD advocate, community builder, and inspiration for this foundation's patient-centered approach.

**Strategic Horizon**: 10-year roadmap (2025-2035) with 5-year detailed plans across 5 strategic phases.

---

### The Plan: 162+ Strategic Documents

This master plan comprises **162+ comprehensive strategic documents** organized across **12 strategic areas**:

1. **Operations** (4 docs): Board governance, financial management, team structure, volunteers
2. **Strategy** (5 docs): Mission/vision, strategic plan, theory of change, impact measurement, annual goals
3. **Patient Education** (8 docs): AATD guides, treatment options, testing roadmap, support groups, patient navigation, community engagement
4. **Additional Services** (18 docs): Insurance appeals, legal support, genetic counseling, clinical trials, telemedicine, career counseling, mental health, travel assistance, AATD University, patient registry, annual conference, medical records portal, specialized programs, concierge service, second opinions, expert witness database
5. **Research & Innovation** (10 docs): Gene therapy, AAT glucometer, rapid testing devices, DNA simplification, mass protein production, drug repurposing, ZZ protein recovery, novel administration methods, patents, research priorities
6. **Medical Education** (4 docs): CME physician education, diagnostic delay/malpractice, medical institution partnerships, AATD-Aware certification
7. **Advocacy** (5 docs): Federal policy, state/local policy, insurance coverage, occupational health, advocacy toolkit
8. **Advocacy & Scale** (6 docs): Website redesign, content/SEO, digital marketing, anonymous data donation, registry monetization, global expansion
9. **Brand** (3 docs): Brand guidelines, messaging framework, storytelling/case studies
10. **Fundraising** (3 docs): Major donor cultivation, corporate partnerships, donor stewardship
11. **Partnerships** (6 docs): Pharmaceutical, genetic testing, academic research, similar organizations, employee giving, fundraising events
12. **Grants** (8 docs): Grants-in (sources, calendar, applications, tracking), Grants-out (research, patient assistance, community, education)

**Total Strategic Content**: 5,000+ pages, $50M+ in projected budgets, 100+ staff positions (full buildout), 10,000+ registry participants target.

---

### Why This Matters

**Current State of AATD**:

- 100,000 Americans have severe AATD (Pi\*ZZ genotype)
- Only 10,000 diagnosed (90% undiagnosed‚Äîliving with "asthma," "COPD," untreated)
- Average diagnostic delay: 5-7 years, 3-4 misdiagnoses
- No cure (only augmentation therapy‚Äîslows progression, doesn't reverse damage)

**Mark Egly Foundation Will Change This**:

- **Diagnosis**: Partner with 23andMe, Invitae (genetic testing‚Äîscreen 1M+ people, identify 5,000+ new AATD patients by Year 5)
- **Research**: Build 10,000-patient registry (world's largest‚Äîaccelerate gene therapy trials, cure within 10-15 years)
- **Support**: Serve 500 patients Year 1 ‚Üí 10,000 by Year 10 (support groups, patient navigation, financial assistance)
- **Advocacy**: Policy change (newborn screening, insurance coverage‚Äîsystemic impact)

---

## Document Index by Phase

### PHASE 1: Foundation Structure (17 Documents)

_Location_: `/foundation-structure/`

**Governance & Legal** (6 docs):

1. ‚úÖ ARTICLES-OF-INCORPORATION.md (Ohio nonprofit, 501(c)(3) application)
2. ‚úÖ BYLAWS.md (Board structure, committees, decision-making)
3. ‚úÖ BOARD-GOVERNANCE-POLICIES.md (Conflict of interest, ethics, fiduciary duties)
4. ‚úÖ SCIENTIFIC-ADVISORY-BOARD-CHARTER.md (Expert oversight, research priorities)
5. ‚úÖ PATIENT-ADVISORY-BOARD-CHARTER.md (Patient voice, program design input)
6. ‚úÖ ETHICS-COMMITTEE-CHARTER.md (IRB-equivalent, biobank oversight)

**Operational Foundation** (6 docs): 7. ‚úÖ ORGANIZATIONAL-STRUCTURE-JOB-DESCRIPTIONS.md (15 positions, Year 1-5 hiring) 8. ‚úÖ FINANCIAL-MANAGEMENT-POLICIES.md (Budgeting, reserves, audit, investment) 9. ‚úÖ INSURANCE-RISK-MANAGEMENT.md (D&O, cyber, liability‚Äî$500K/year coverage) 10. ‚úÖ DATA-PRIVACY-SECURITY-POLICIES.md (HIPAA, GDPR, patient data protection) 11. ‚úÖ VENDOR-MANAGEMENT-PROCUREMENT.md (IT, legal, biobank‚Äî$500K contracts) 12. ‚úÖ CRISIS-COMMUNICATION-PLAN.md (Data breaches, leadership transitions, PR crises)

**Compliance** (5 docs): 13. ‚úÖ HIPAA-COMPLIANCE-PROGRAM.md (Patient data handling, training, audits) 14. ‚úÖ FUNDRAISING-COMPLIANCE-STATE-REGISTRATIONS.md (Charitable solicitation‚Äî40 states) 15. ‚úÖ LOBBYING-ADVOCACY-COMPLIANCE.md (501(c)(3) limits, 501(c)(4) coordination) 16. ‚úÖ INTERNATIONAL-OPERATIONS-COMPLIANCE.md (GDPR, cross-border data, foreign registration) 17. ‚úÖ ANNUAL-COMPLIANCE-CALENDAR.md (990 filing, audits, board meetings‚Äînever miss deadline)

**Phase 1 Purpose**: Build ironclad legal/operational foundation‚Äîno shortcuts, do it right from Day 1.

---

### PHASE 2: Patient Services & Programs (18 Documents)

_Location_: `/patient-services-programs/`

**Support Programs** (6 docs): 18. ‚úÖ PEER-SUPPORT-GROUPS.md (Virtual/in-person, 20 groups by Year 5, trained facilitators) 19. ‚úÖ ONE-ON-ONE-MENTORSHIP-PROGRAM.md (Match newly diagnosed with veteran patients) 20. ‚úÖ CAREGIVER-FAMILY-SUPPORT-PROGRAM.md (Spouse, parent, child support‚Äîwhole family impacted) 21. ‚úÖ MENTAL-HEALTH-COUNSELING-REFERRALS.md (Depression, anxiety‚Äî50% of AATD patients) 22. ‚úÖ EMERGENCY-FINANCIAL-ASSISTANCE-FUND.md ($500-$2K grants, rent, meds, oxygen‚Äîcrisis relief) 23. ‚úÖ TRAVEL-ASSISTANCE-PROGRAM.md (Flights, lodging for clinical trials, specialized care)

**Navigation & Education** (6 docs): 24. ‚úÖ PATIENT-NAVIGATION-PROGRAM.md (1:1 navigators, insurance, treatment, social services) 25. ‚úÖ NEWLY-DIAGNOSED-WELCOME-PACKET.md (Comprehensive guide‚Äî"You have AATD, here's what's next") 26. ‚úÖ TREATMENT-DECISION-SUPPORT-TOOLS.md (Augmentation vs. not, lung transplant‚Äîinformed consent) 27. ‚úÖ INSURANCE-ADVOCACY-ASSISTANCE.md (Appeal denials, prior authorizations‚Äî80% success rate) 28. ‚úÖ GENETIC-COUNSELING-PROGRAM.md (Family testing, carrier risks, reproductive planning) 29. ‚úÖ ONLINE-EDUCATION-PORTAL.md (200+ articles, videos, webinars‚Äîself-serve learning)

**Community Building** (6 docs): 30. ‚úÖ ANNUAL-PATIENT-CONFERENCE.md (500 attendees, experts, patients, advocacy‚Äîflagship event) 31. ‚úÖ REGIONAL-PATIENT-SUMMITS.md (10 cities, smaller, local connections) 32. ‚úÖ ONLINE-COMMUNITY-PLATFORM.md (Forum, private groups, 5,000 members by Year 5) 33. ‚úÖ PATIENT-NEWSLETTER.md (Monthly, 10,000 subscribers, stories, research updates) 34. ‚úÖ PATIENT-STORY-COLLECTION-PROGRAM.md (Video testimonials, written stories‚Äîadvocacy, fundraising) 35. ‚úÖ VOLUNTEER-PROGRAM-STRUCTURE.md (50 volunteers, event support, peer mentors, ambassadors)

**Phase 2 Purpose**: Serve patients TODAY while building for tomorrow‚Äîtangible impact from Day 1.

---

### PHASE 3: Research & Innovation (17 Documents)

_Location_: `/research-innovation/`

**Research Programs** (6 docs): 36. ‚úÖ PATIENT-REGISTRY-DESIGN-IMPLEMENTATION.md (10,000 patients, genetic+clinical+biospecimens) 37. ‚úÖ BIOBANK-SPECIMEN-REPOSITORY.md (Plasma, serum, DNA‚Äî5,000 samples, $1M infrastructure) 38. ‚úÖ RESEARCH-GRANT-PROGRAM.md ($500K Year 1 ‚Üí $5M Year 5 awarded to scientists) 39. ‚úÖ YOUNG-INVESTIGATOR-AWARDS.md (Emerging scholars, $50K-$100K, build next generation) 40. ‚úÖ COLLABORATIVE-RESEARCH-NETWORK.md (10 academic centers, shared protocols, multi-site studies) 41. ‚úÖ DATA-SHARING-OPEN-SCIENCE-POLICY.md (Make data public‚Äîaccelerate discovery, not hoard)

**Innovation Focus Areas** (6 docs): 42. ‚úÖ GENE-THERAPY-RESEARCH-PROGRAM.md (AAV, CRISPR, mRNA‚Äîcure-focused, $10M over 5 years) 43. ‚úÖ RAPID-DIAGNOSTIC-INNOVATION-FUND.md (Point-of-care AAT test, genetic screening‚Äîdiagnosis acceleration) 44. ‚úÖ AUGMENTATION-THERAPY-ALTERNATIVES.md (Small molecules, nanoparticles‚Äîbeyond infusion) 45. ‚úÖ LIVER-DISEASE-RESEARCH-INITIATIVE.md (Cirrhosis, transplant‚Äî20% AATD patients, under-studied) 46. ‚úÖ EXACERBATION-PREDICTION-TOOLS.md (AI, wearables‚Äîpredict flare-ups, intervene early) 47. ‚úÖ QUALITY-OF-LIFE-OUTCOMES-RESEARCH.md (Beyond FEV1‚Äîwhat matters to patients, PROs)

**Research Operations** (5 docs): 48. ‚úÖ INSTITUTIONAL-REVIEW-BOARD-PROCESS.md (Ethics review, Foundation studies‚Äîprotect patients) 49. ‚úÖ DATA-MANAGEMENT-STANDARDS.md (REDCap, FHIR, interoperability‚Äîhigh-quality data) 50. ‚úÖ PUBLICATION-POLICY-AUTHORSHIP-GUIDELINES.md (Fairness, transparency, acknowledge Foundation) 51. ‚úÖ INTELLECTUAL-PROPERTY-POLICY.md (Patents, licensing‚Äîbalance revenue + access) 52. ‚úÖ RESEARCH-PARTNERSHIP-EVALUATION-CRITERIA.md (Which pharma to partner with‚Äîmission-aligned only)

**Phase 3 Purpose**: Build world-class research infrastructure‚Äîaccelerate path to cure.

---

### PHASE 4: Fundraising & Partnerships (17 Documents)

_Location_: `/fundraising-partnerships/`

**Revenue Streams** (6 docs): 53. ‚úÖ INDIVIDUAL-GIVING-PROGRAM.md ($200K Year 1 ‚Üí $5M Year 5, donor cultivation, stewardship) 54. ‚úÖ MAJOR-GIFTS-PROGRAM.md ($10K+ donors, personal relationships, $2M Year 5 target) 55. ‚úÖ PLANNED-GIVING-LEGACY-PROGRAM.md (Bequests, estates‚Äî$500K-$1M long-term) 56. ‚úÖ CORPORATE-SPONSORSHIP-PROGRAM.md (Non-pharma‚Äîmedical devices, insurance, $500K/year) 57. ‚úÖ FOUNDATION-GRANTS-PROGRAM.md (Patient Advocate Foundation, RRF‚Äî$1M-$2M/year) 58. ‚úÖ ONLINE-FUNDRAISING-DIGITAL-CAMPAIGNS.md (Giving Tuesday, Rare Disease Day‚Äî$200K/year)

**Events** (5 docs): 59. ‚úÖ SIGNATURE-FUNDRAISING-GALA.md ($500K net Year 1 ‚Üí $2M Year 5, black-tie, 400 attendees) 60. ‚úÖ ENDURANCE-EVENTS-PROGRAM.md (Breathe Easy 5K, marathons‚Äî$300K/year, patient engagement) 61. ‚úÖ GOLF-TOURNAMENT-LOGISTICS.md ($150K net, corporate teams, annual tradition) 62. ‚úÖ VIRTUAL-FUNDRAISING-EVENTS.md (Webathons, online auctions‚Äî$100K/year, low overhead) 63. ‚úÖ THIRD-PARTY-FUNDRAISING-TOOLKIT.md (DIY events‚Äîpatients host, Foundation supports, $50K/year)

**Strategic Partnerships** (6 docs): 64. ‚úÖ PHARMACEUTICAL-PARTNERSHIPS.md (Grifols, CSL, Takeda‚Äî$2M-$3M/year, research funding, unrestricted grants) 65. ‚úÖ GENETIC-TESTING-PARTNERSHIPS.md (23andMe, Invitae‚Äîscreen 1M people, identify 5,000 AATD patients) 66. ‚úÖ HEALTHCARE-SYSTEM-PARTNERSHIPS.md (Cleveland Clinic, Mayo‚Äîcenters of excellence, referrals) 67. ‚úÖ RARE-DISEASE-COALITION-ENGAGEMENT.md (NORD, EveryLife‚Äîamplify advocacy, share best practices) 68. ‚úÖ ACADEMIC-MEDICAL-CENTER-RELATIONSHIPS.md (10 university partnerships‚Äîresearch, training, credibility) 69. ‚úÖ PATIENT-ORGANIZATION-COLLABORATIONS.md (AlphaNet, Alpha-1 Foundation‚Äîcoopetition, not duplication)

**Phase 4 Purpose**: Diversified revenue‚Äî$500K Year 1 ‚Üí $10M Year 5, financial sustainability.

---

### PHASE 5: Advocacy & Scale (20 Documents)

_Location_: `/advocacy-scale/`

**Public Awareness** (6 docs): 70. ‚úÖ WEBSITE-REDESIGN-INFORMATION-ARCHITECTURE.md (User personas, IA, patient-first design, $75K) 71. ‚úÖ CONTENT-STRATEGY-SEO-PLAN.md (200+ articles, keyword research, top Google rankings, $150K/year) 72. ‚úÖ DIGITAL-MARKETING-SOCIAL-MEDIA-STRATEGY.md (Paid ads, Facebook, Instagram, influencers, $160K/year) 73. ‚úÖ PUBLIC-RELATIONS-MEDIA-OUTREACH.md (Press releases, TV, newspapers‚Äînational coverage) 74. ‚úÖ PATIENT-STORIES-MEDIA-CAMPAIGN.md (Video testimonials, viral potential, humanize AATD) 75. ‚úÖ RARE-DISEASE-DAY-CAMPAIGN.md (Feb 28, flagship awareness event‚Äî$50K budget, 1M impressions)

**Policy Advocacy** (5 docs): 76. ‚úÖ NEWBORN-SCREENING-ADVOCACY-STRATEGY.md (Add AATD to state panels‚Äîprevent lung damage) 77. ‚úÖ INSURANCE-COVERAGE-POLICY-WORK.md (Medicare, Medicaid, private‚Äîaugmentation coverage, genetic testing) 78. ‚úÖ RESEARCH-FUNDING-ADVOCACY.md (NIH, DOD‚Äîincrease AATD research budget from $5M to $50M) 79. ‚úÖ GRASSROOTS-ADVOCACY-TRAINING.md (Train 100 patient advocates‚Äîcongressional meetings, storytelling) 80. ‚úÖ LEGISLATIVE-TRACKING-ENGAGEMENT.md (Monitor bills, testify, coalition letters‚Äîproactive policy)

**Healthcare Professional Engagement** (4 docs): 81. ‚úÖ PHYSICIAN-EDUCATION-PROGRAM.md (CME courses, "Think AATD"‚Äîtrain 10,000 pulmonologists) 82. ‚úÖ GENETIC-COUNSELOR-TRAINING.md (AATD-specific curriculum‚Äîexpert counselors) 83. ‚úÖ TESTING-GUIDELINES-PROMOTION.md (ATS/ERS guidelines‚Äîstandardize who gets tested) 84. ‚úÖ MEDICAL-CONFERENCE-PRESENCE.md (ATS, ERS, CHEST‚ÄîFoundation booth, research presentations)

**Data & Scale Programs** (5 docs): 85. ‚úÖ ANONYMOUS-DATA-DONATION-PROGRAM.md (10,000 participants, privacy framework, research acceleration) 86. ‚úÖ PATIENT-REGISTRY-MONETIZATION-STRATEGY.md ($1.5M-$2M/year, pharma data licensing‚Äîethical revenue) 87. ‚úÖ TAX-DEDUCTION-STRATEGY-DNA-DONATION.md (IRS ruling, $1K-$5K deduction/patient‚Äîinnovative incentive) 88. ‚úÖ GLOBAL-EXPANSION-BLUEPRINT.md (Europe, Asia‚Äî500-1,000 international patients, GDPR compliance) 89. ‚úÖ MASTER-PLAN-INDEX-IMPLEMENTATION-SUMMARY.md (This document‚Äîroadmap integration)

**Phase 5 Purpose**: Scale impact‚Äî10,000 patients served, 50% diagnosis rate, policy wins, global reach.

---

## Implementation Priorities

### Priority Tier 1: MUST HAVE (Year 1 Launch Requirements)

**Governance & Legal** (Do FIRST‚Äîcan't operate without):

1. Articles of Incorporation (Q1 Month 1‚Äîfile with Ohio)
2. Bylaws (Q1 Month 1‚ÄîBoard approval)
3. 501(c)(3) Application (Q1 Month 2‚ÄîIRS submission, 6-month wait)
4. Board Governance Policies (Q1 Month 2‚Äîconflict of interest, ethics)
5. HIPAA Compliance Program (Q1 Month 3‚Äîbefore collecting patient data)

**Foundational Programs** (Launch with tangible patient impact): 6. Peer Support Groups (Q2 Month 4‚Äîvirtual first, low-cost, high-impact) 7. Patient Navigation Program (Q2 Month 5‚Äîhire 1 navigator, serve 50 patients) 8. Newly Diagnosed Welcome Packet (Q2 Month 5‚Äîdigital PDF, no printing cost) 9. Online Education Portal (Q3 Month 6‚ÄîWordPress site, 50 articles Year 1) 10. Individual Giving Program (Q1 Month 1‚Äîneed revenue immediately, donor database)

**Core Infrastructure**: 11. Organizational Structure & Job Descriptions (Q1 Month 1‚Äîhire Executive Director first) 12. Financial Management Policies (Q1 Month 2‚Äîopen bank account, QuickBooks) 13. Data Privacy & Security Policies (Q1 Month 3‚Äîprotect patient data from Day 1)

**Year 1 Priority Budget**: $150K-$200K (lean startup‚ÄîExecutive Director, 1 Program Manager, 1 Navigator, basic tech)

---

### Priority Tier 2: SHOULD HAVE (Year 1-2 Expansion)

**Research Foundation** (Build for Year 2+): 14. Patient Registry Design (Year 1 Q4‚Äîplan, Year 2 Q1 launch‚Äîrecruit 500) 15. Research Grant Program (Year 2 Q1‚Äî$100K pilot grants, 2-3 awards) 16. Scientific Advisory Board Charter (Year 1 Q3‚Äîrecruit SAB, approve research priorities)

**Fundraising Growth**: 17. Major Gifts Program (Year 1 Q3‚Äîafter 6 months operations, case studies ready) 18. Signature Fundraising Gala (Year 1 Q4‚Äîplan, Year 2 Q1 execute‚Äînet $200K+) 19. Corporate Sponsorship Program (Year 2 Q1‚Äîapproach device companies, insurance)

**Patient Services Expansion**: 20. Annual Patient Conference (Year 2 Q3‚Äî200 attendees, $150K budget) 21. Emergency Financial Assistance Fund (Year 1 Q4‚Äî$25K fund, help 25-50 families) 22. Insurance Advocacy Assistance (Year 2 Q1‚Äîhire specialist, appeals program)

**Year 1-2 Budget**: $500K-$1M cumulative (prove model, build credibility)

---

### Priority Tier 3: NICE TO HAVE (Year 3-5 Maturity)

**Advanced Research**: 23. Biobank Specimen Repository (Year 3‚Äî$1M infrastructure, once registry has 2,000+ patients) 24. Gene Therapy Research Program (Year 3‚Äî$2M commitment, once fundraising $5M+/year) 25. Collaborative Research Network (Year 4‚Äî10 centers, requires $3M-$5M budget)

**Scale Programs**: 26. Regional Patient Summits (Year 3‚Äî10 cities, requires $200K+/year travel, staff) 27. Genetic Testing Partnerships (Year 3‚Äînegotiate with 23andMe, need 5,000 patients to attract them) 28. Registry Monetization (Year 3‚Äîonce 3,000+ patients, pharma interested)

**Global Expansion**: 29. International Operations (Year 5‚ÄîEurope, Asia, requires $500K+/year, legal complexity)

**Year 3-5 Budget**: $3M-$10M/year (mature operations, research powerhouse)

---

## Document Interdependencies

### Critical Path Dependencies (Must Complete in Order)

**Legal Before Everything**:

- Articles of Incorporation ‚Üí Bylaws ‚Üí 501(c)(3) Application ‚Üí (wait 6 months) ‚Üí 501(c)(3) Approval ‚Üí Can issue tax-deductible receipts

**Governance Before Programs**:

- Bylaws ‚Üí Board Governance Policies ‚Üí Board recruits ‚Üí Scientific Advisory Board Charter ‚Üí SAB recruits ‚Üí Research Grant Program launches
- (Can't give research grants without SAB to review‚Äîscientific credibility)

**Infrastructure Before Data Collection**:

- HIPAA Compliance Program ‚Üí Data Privacy & Security Policies ‚Üí Patient Registry Design ‚Üí Registry Launch
- (Can't collect patient data without HIPAA compliance‚Äîlegal requirement)

**Fundraising Before Scaling**:

- Individual Giving Program (Year 1) ‚Üí Major Gifts Program (Year 2) ‚Üí Foundation Grants (Year 2-3) ‚Üí Registry Monetization (Year 3-5)
- (Need $500K-$1M/year revenue before can afford registry infrastructure $1M+)

---

### Parallel Opportunities (Can Execute Simultaneously)

**Year 1 Parallelization**:

- ‚úÖ Peer Support Groups + Patient Navigation + Welcome Packet (all patient services‚Äîdifferent staff, no conflict)
- ‚úÖ Individual Giving + Online Fundraising (donor cultivation happens while digital campaigns run)
- ‚úÖ Website Redesign + Content Strategy (web developer builds site while content writer drafts articles)

**Year 2-3 Parallelization**:

- ‚úÖ Registry Recruitment + Research Grant Awards (registry grows while funded researchers publish)
- ‚úÖ Gala + Endurance Events + Golf Tournament (different event committees, spread across quarters)
- ‚úÖ Physician Education + Patient Conference (different audiences, complementary)

---

### Synergistic Clusters (Documents That Amplify Each Other)

**Cluster 1: Diagnosis Acceleration**:

- Genetic Testing Partnerships (23andMe screens) ‚Üí Genetic Counseling Program (counsel positives) ‚Üí Patient Navigation (enroll in care) ‚Üí Patient Registry (collect data) ‚Üí Research (study newly diagnosed)
- **Synergy**: Each step feeds next‚Äî1M screened ‚Üí 5K diagnosed ‚Üí 3K enroll registry ‚Üí research accelerates

**Cluster 2: Research Flywheel**:

- Patient Registry ‚Üí Biobank ‚Üí Research Grants ‚Üí Publications ‚Üí Registry Credibility ‚Üí Pharma Partnerships ‚Üí Registry Revenue ‚Üí More Research Grants
- **Synergy**: Virtuous cycle‚Äîbetter registry ‚Üí more research ‚Üí better registry

**Cluster 3: Patient Journey**:

- Newly Diagnosed Welcome Packet ‚Üí Peer Support Groups ‚Üí Patient Navigation ‚Üí Annual Conference ‚Üí Patient Advisory Board (veteran patients) ‚Üí Volunteer Program (give back)
- **Synergy**: Patients progress from "scared, newly diagnosed" ‚Üí "supported, educated" ‚Üí "advocates, leaders"

---

## 5-Year Execution Timeline

### Year 1 (2025): Foundation Launch

**Q1 (Jan-Mar): Legal & Infrastructure**

- ‚úÖ Incorporate (Ohio)
- ‚úÖ File 501(c)(3)
- ‚úÖ Adopt Bylaws
- ‚úÖ Recruit initial Board (7 members)
- ‚úÖ Hire Executive Director
- ‚úÖ Establish bank account, accounting system
- **Budget**: $50K (legal fees, ED salary 3 months, setup costs)

**Q2 (Apr-Jun): Program Launch**

- ‚úÖ Launch Peer Support Groups (2 virtual groups, 30 patients)
- ‚úÖ Hire Patient Navigator (serve 50 patients)
- ‚úÖ Publish Welcome Packet (PDF, 50 downloads)
- ‚úÖ Start Individual Giving (250 donors @ $500 avg = $125K)
- **Budget**: $150K (staff, programs)

**Q3 (Jul-Sep): Content & Expansion**

- ‚úÖ Launch education portal (WordPress, 50 articles)
- ‚úÖ Recruit Scientific Advisory Board (5 members)
- ‚úÖ Plan Patient Registry (design, IRB submission)
- ‚úÖ Start Major Gifts (identify 50 prospects)
- **Budget**: $150K

**Q4 (Oct-Dec): Momentum Building**

- ‚úÖ Plan Year 2 Gala (venue, date, committee)
- ‚úÖ Launch Emergency Financial Assistance ($25K fund)
- ‚úÖ Grow support groups (5 groups, 75 patients)
- ‚úÖ Year-End donor campaign ($75K)
- **Budget**: $150K

**Year 1 Total**: $500K budget, 200 patients served, 300 donors, 501(c)(3) approved

---

### Year 2 (2026): Proof of Concept

**Key Achievements**:

- ‚úÖ Patient Registry launches (500 participants)
- ‚úÖ First Research Grants awarded ($100K, 3 projects)
- ‚úÖ Signature Gala (net $200K)
- ‚úÖ Annual Patient Conference (200 attendees)
- ‚úÖ Pharmaceutical partnership (Grifols, $200K)

**Budget**: $1M, **Revenue**: $800K (need $200K reserves/deficit coverage)

**Metrics**: 500 patients served, 1,000 donors, 500 registry participants

---

### Year 3 (2027): Scaling Impact

**Key Achievements**:

- ‚úÖ Registry 2,000 patients
- ‚úÖ Biobank launches (500 samples)
- ‚úÖ Genetic Testing Partnership (23andMe pilot, 10K screened)
- ‚úÖ Registry Monetization starts ($300K revenue)
- ‚úÖ Regional Summits (5 cities, 500 attendees)

**Budget**: $3M, **Revenue**: $2.5M (still building reserves)

**Metrics**: 2,000 patients served, 3,000 donors, 2,000 registry

---

### Year 4 (2028): Research Powerhouse

**Key Achievements**:

- ‚úÖ Registry 5,000 patients
- ‚úÖ Gene Therapy Partnership (pharma co-funds, $2M)
- ‚úÖ Registry Revenue $1M/year
- ‚úÖ Collaborative Research Network (10 centers)
- ‚úÖ Newborn Screening (2 states pilot)

**Budget**: $5M, **Revenue**: $5M (break-even)

**Metrics**: 5,000 patients served, 5,000 donors, 5,000 registry

---

### Year 5 (2029): Sustainable & Mature

**Key Achievements**:

- ‚úÖ Registry 10,000 patients (world's largest)
- ‚úÖ Registry Revenue $2M/year
- ‚úÖ Genetic Testing scaled (100K+ screened/year)
- ‚úÖ International expansion (Europe, 500 patients)
- ‚úÖ Diagnosis rate: 15% nationally (up from 10%‚Äî5,000 additional patients diagnosed via Foundation efforts)

**Budget**: $10M, **Revenue**: $10M+ (surplus starts‚Äîendowment building)

**Metrics**: 10,000 patients served, 10,000 donors, 10,000 registry, $2M endowment

---

## Budget Summary

### 5-Year Cumulative Budget

| Year       | Operating Budget | Capital/Infrastructure         | Total      | Primary Revenue Sources                                                                                          |
| ---------- | ---------------- | ------------------------------ | ---------- | ---------------------------------------------------------------------------------------------------------------- |
| **Year 1** | $450K            | $50K (legal, setup)            | $500K      | Individual giving ($300K), Foundation grants ($150K), In-kind ($50K)                                             |
| **Year 2** | $800K            | $200K (registry, IT)           | $1M        | Individual ($400K), Events ($250K), Pharma ($200K), Foundation grants ($150K)                                    |
| **Year 3** | $2.5M            | $500K (biobank)                | $3M        | Individual ($1M), Events ($500K), Pharma ($500K), Registry ($300K), Foundation grants ($500K), Corporate ($200K) |
| **Year 4** | $4M              | $1M (gene therapy pilot)       | $5M        | Individual ($2M), Events ($800K), Pharma ($1M), Registry ($800K), Foundation grants ($400K)                      |
| **Year 5** | $8M              | $2M (international, endowment) | $10M       | Individual ($3M), Events ($1.5M), Pharma ($2M), Registry ($2M), Foundation grants ($1M), Corporate ($500K)       |
| **Total**  | **$15.75M**      | **$3.75M**                     | **$19.5M** | Diversified, no single source >30% by Year 5                                                                     |

---

### Budget Allocation by Category (Year 5 Steady-State)

| Category                  | Budget   | % of Total | Key Investments                                                                                 |
| ------------------------- | -------- | ---------- | ----------------------------------------------------------------------------------------------- |
| **Patient Services**      | $2M      | 20%        | Navigation, support groups, financial assistance, conferences                                   |
| **Research Programs**     | $3M      | 30%        | Grant awards ($2M), Registry operations ($500K), Biobank ($500K)                                |
| **Fundraising**           | $2M      | 20%        | Events ($800K), Development staff ($600K), Donor stewardship ($400K), Digital marketing ($200K) |
| **Advocacy & Awareness**  | $1M      | 10%        | Policy ($300K), Physician education ($300K), PR/media ($400K)                                   |
| **Operations**            | $1.5M    | 15%        | Staff salaries (15 FTE), IT, office, insurance, legal                                           |
| **Strategic Initiatives** | $500K    | 5%         | International expansion, new programs, innovation                                               |
| **Total**                 | **$10M** | **100%**   | Balanced‚Äîimpact + sustainability                                                                |

---

## Success Metrics Dashboard

### Primary Outcomes (Mission Impact)

**Diagnosis Rate** (Goal: 10% ‚Üí 50% over 10 years):

- Year 1: 10.5% (500 new diagnoses via Foundation‚Äîdirectly screened or physician educated)
- Year 3: 12% (2,000 cumulative new diagnoses)
- Year 5: 15% (5,000 cumulative‚Äîmeasurable national impact)
- Year 10: 50% (45,000 additional diagnoses‚Äîtransforms AATD landscape)

**Research Acceleration** (Goal: Cure within 10-15 years):

- Year 1: 2 publications citing Foundation data
- Year 3: 15 publications, 1 gene therapy trial enrolling
- Year 5: 50 publications, 3 gene therapy trials, 1 new diagnostic approved
- Year 10: 100+ publications, gene therapy FDA-approved (curative)

**Patient Reach** (Goal: Serve every AATD patient):

- Year 1: 200 patients directly served
- Year 3: 2,000 patients served (support, navigation, programs)
- Year 5: 10,000 patients (10% of diagnosed population‚Äîsignificant penetration)
- Year 10: 50,000+ patients (50% of diagnosed‚ÄîFoundation = central resource)

---

### Operational Metrics (Execution Health)

**Financial Sustainability**:

- ‚úÖ Year 1: Deficit $200K (planned, covered by reserves)
- ‚úÖ Year 3: Deficit $500K (registry investment, planned)
- ‚úÖ Year 4: Break-even
- ‚úÖ Year 5: Surplus $500K (start building endowment)
- ‚úÖ Year 10: $10M endowment (covers 50% operating costs‚Äîperpetuity)

**Donor Growth**:

- Year 1: 300 donors, $500 average gift
- Year 3: 3,000 donors, $350 average (more small donors‚Äîgrassroots base)
- Year 5: 10,000 donors, $300 average (mass movement‚Äîpatient families + general public)
- Year 10: 50,000 donors, $250 average (patient + allies‚Äîdeeply loyal base)

**Registry Quality**:

- Year 1: 500 participants, 80% data completeness (baseline, physician-reported)
- Year 3: 2,000 participants, 90% completeness (EHR integration‚Äîautomated)
- Year 5: 10,000 participants, 95% completeness (gold standard‚Äîlongitudinal, validated)
- Year 10: 20,000 participants, 20-year follow-up (world's most comprehensive AATD dataset)

**Program Efficiency** (Cost per Patient Served):

- Year 1: $2,500/patient ($500K budget / 200 patients‚Äîhigh, startup phase)
- Year 3: $1,500/patient ($3M / 2,000‚Äîscale economies)
- Year 5: $1,000/patient ($10M / 10,000‚Äîmature efficiency)
- Year 10: $800/patient ($40M / 50,000‚Äîoptimal scale)

---

## Resource Requirements

### Staffing Plan (Headcount Growth)

**Year 1** (4 FTE):

1. Executive Director (full-time, $120K)
2. Program Manager (full-time, $65K)
3. Patient Navigator (full-time, $55K)
4. Development Coordinator (full-time, $50K)

**Year 2** (7 FTE):

- Add: Chief Science Officer ($150K), Registry Coordinator ($60K), Events Manager ($55K)

**Year 3** (12 FTE):

- Add: COO ($130K), Major Gifts Officer ($80K), Communications Director ($85K), 2 additional Navigators ($55K each)

**Year 5** (20 FTE):

- Full team: Executive, Science, COO, CFO, Development (4 staff), Programs (6 staff), Communications (2 staff), Operations (2 staff)

**Year 10** (40 FTE):

- Mature organization: Executive suite (5), Development (8), Programs (15), Research (8), Advocacy (4)

---

### Technology Infrastructure

**Year 1** ($25K):

- Website (WordPress, $10K build + $2K/year hosting)
- Donor database (Salesforce Nonprofit, $5K/year)
- Email marketing (Mailchimp, $1K/year)
- Cloud storage (Google Workspace, $2K/year)

**Year 2** ($75K):

- Registry database (REDCap, $30K setup + $10K/year)
- Video conferencing (Zoom, $2K/year)
- CRM upgrades ($10K)

**Year 3** ($150K):

- Biobank management system ($50K)
- EHR integrations (FHIR API, $30K/year)
- Security upgrades (penetration testing, $20K/year)

**Year 5** ($300K/year):

- Advanced analytics (Tableau, $20K/year)
- AI tools (patient matching, $50K/year)
- International infrastructure (GDPR, $50K/year)

---

### Board & Advisory Composition

**Board of Directors** (Year 1: 7, Year 5: 12):

- Executive Director (ex-officio)
- 3 patient/family representatives (lived experience‚Äîcritical voice)
- 2 physicians (pulmonology, hepatology‚Äîclinical expertise)
- 2 business leaders (fundraising, strategy‚Äîoperational guidance)
- 1 attorney (governance‚Äîlegal oversight)
- 1 accountant (financial‚Äîaudit committee chair)
- 2 community leaders (diversity‚Äîracial, geographic, professional)

**Scientific Advisory Board** (Year 1: 5, Year 5: 12):

- 3 AATD experts (Stoller, Sandhaus, Strange‚Äîtop tier)
- 2 gene therapy researchers (cure-focused)
- 2 diagnostic innovators (screening, testing)
- 2 basic scientists (AAT biology, proteostasis)
- 3 early-career investigators (fresh perspectives)

**Patient Advisory Board** (Year 1: 10, Year 5: 25):

- Diverse patients (age 25-75, Pi*ZZ and Pi*SZ, lung and liver, augmentation users and non-users)
- Caregivers (2-3 spouses, parents‚Äîfamily voice)
- Newly diagnosed (2-3‚Äîremember what it's like)

---

## Risk Matrix

### HIGH RISK (Mitigate Aggressively)

**Risk 1: 501(c)(3) Application Denied**

- **Impact**: Can't issue tax-deductible receipts‚Äîfundraising crippled, donors won't give
- **Likelihood**: Low (5%‚Äîwell-structured application, attorney-drafted)
- **Mitigation**: Hire experienced nonprofit attorney ($10K‚Äîworth every penny), submit complete application, respond promptly to IRS questions
- **Contingency**: If denied‚Äîappeal (90% success rate on appeal), or operate as 501(c)(4) social welfare org (less preferred but viable)

**Risk 2: Data Breach (Patient Registry Hacked)**

- **Impact**: HIPAA violation ($50K fine/record‚Äîpotential $50M if 1,000 patients), reputation destroyed, registry collapses
- **Likelihood**: Low-Moderate (10%‚Äîhealthcare = prime target for hackers)
- **Mitigation**: Cyber liability insurance ($2M coverage, $20K/year), penetration testing (annual, $15K), encryption (AES-256, data at rest + in transit), staff training (phishing simulations quarterly)
- **Contingency**: Incident response plan (forensics firm on retainer, notify patients <72 hours, offer credit monitoring, public transparency)

**Risk 3: Executive Director Departure (Year 1-2)**

- **Impact**: Loss of institutional knowledge, donor relationships, momentum stalls
- **Likelihood**: Moderate (20%‚Äîstartup nonprofits = high turnover, burnout)
- **Mitigation**: Competitive comp ($120K + benefits‚Äîabove sector median), strong Board support (monthly meetings, not micromanaging), clear succession plan (COO cross-trained)
- **Contingency**: Interim ED (Board member steps in 3-6 months), national search (6 months), maintain continuity via COO

---

### MEDIUM RISK (Monitor & Manage)

**Risk 4: Pharma Partnership Fails to Materialize**

- **Impact**: Revenue shortfall ($500K-$1M/year‚Äîdelay registry expansion, biobank)
- **Likelihood**: Moderate (30%‚Äîpharma priorities shift, budget cuts)
- **Mitigation**: Diversify (3-5 pharma partners, not 1‚Äîno single point of failure), contract multi-year (lock in commitments), deliver value (demonstrate ROI‚Äîpharma renews)
- **Contingency**: Foundation grants (NEA, RRF‚Äîalternative funding), registry monetization (academic customers‚Äîsmaller checks, but more of them)

**Risk 5: Low Registry Enrollment (<500 Year 1)**

- **Impact**: Research plans delayed, pharma partnerships less attractive (need 1,000+ patients to interest them)
- **Likelihood**: Moderate (30%‚Äîpatient recruitment always challenging)
- **Mitigation**: Multi-channel recruitment (patient orgs, pulmonologists, genetic testing partners‚Äînot just one source), incentives ($50 gift card, altruism messaging, trial recruitment priority), simplify enrollment (online portal, 10 minutes)
- **Contingency**: Extend timeline (2 years to 1,000 patients instead of 1 year‚Äîslower but acceptable), partner with AlphaNet (share registry‚Äîcollaborative not competitive)

---

### LOW RISK (Accept & Monitor)

**Risk 6: Event Revenue Underperforms**

- **Impact**: Shortfall $100K-$200K/year (planned gala nets $200K, actual nets $100K)
- **Likelihood**: Moderate (40%‚Äîevents = volatile, economy-dependent)
- **Mitigation**: Conservative budgeting (budget 70% of goal‚Äîexceed expectations), multiple events (5 events = diversification, not 1 gala), corporate sponsorships (pre-sell $100K‚Äîguaranteed revenue)
- **Contingency**: Online fundraising surge (Giving Tuesday, Rare Disease Day‚Äîoffset event shortfall)

**Risk 7: Competitive Landscape (AlphaNet, Alpha-1 Foundation Scale)**

- **Impact**: Donor confusion ("Which Alpha-1 org do I give to?"), market share loss
- **Likelihood**: Low-Moderate (20%‚Äîexisting orgs may expand, but Foundation differentiates)
- **Mitigation**: Clear positioning ("Mark Egly Foundation = research + diagnosis acceleration, AlphaNet = care management, Alpha-1 Foundation = advocacy"‚Äîdifferent niches), collaboration (joint programs‚Äîexpand pie, not fight over slices)
- **Contingency**: Merger discussions (if competition becomes destructive‚Äîconsider merging registries, combining strengths, serve community better)

---

## Quick Start Guide

### FOR BOARD MEMBERS: First 100 Days

**Week 1: Governance Foundation**

- [ ] Review & approve Articles of Incorporation
- [ ] Review & approve Bylaws
- [ ] Sign conflict of interest statements
- [ ] Review Board Governance Policies

**Week 2-4: Financial Setup**

- [ ] Open bank account (require 2 Board signatures)
- [ ] Approve initial budget ($500K Year 1)
- [ ] Set up QuickBooks (COO/Treasurer)
- [ ] File 501(c)(3) application (attorney-led)

**Week 5-8: Fundraising Launch**

- [ ] Each Board member: Personal gift ($1K-$10K‚Äîlead by example)
- [ ] Each Board member: Submit list of 20 donor prospects
- [ ] Plan Year-End campaign (Giving Tuesday, December)

**Week 9-12: Program Planning**

- [ ] Approve peer support group launch (2 virtual groups)
- [ ] Approve patient navigator hire (1 FTE, start recruiting)
- [ ] Approve education portal plan (WordPress, 50 articles Year 1)

**Ongoing (Monthly Board Meetings)**:

- Review financials (budget vs. actual, cash flow)
- Approve major contracts (>$10K‚Äîattorney, IT vendor, biobank)
- Strategic discussions (registry design, pharma partnerships)
- Fundraising updates (pipeline, closed gifts, stewardship)

---

### FOR EXECUTIVE DIRECTOR: First Year Roadmap

**Q1: Foundation & Fundraising**

- Hire initial team (Program Manager, Navigator, Development Coordinator‚Äî3 roles, 60 days to fill)
- Set up operations (office [virtual OK], accounting, insurance, IT)
- Launch individual giving (donor database, website donate button, 100 donors by March)
- File 501(c)(3) (attorney, expect 6-month wait‚Äîplan accordingly)

**Q2: Patient Programs Launch**

- Peer support groups (recruit facilitators, train, launch 2 groups‚Äî30 patients)
- Patient navigation (serve first 20 patients, refine model, scale to 50 by June)
- Welcome packet (create PDF, distribute to AlphaNet, pulmonologists‚Äî50 downloads/month)
- Education portal (WordPress site, 25 articles by June, SEO optimization)

**Q3: Research Foundation**

- Recruit Scientific Advisory Board (5 members‚Äî2 AATD experts, 2 researchers, 1 clinician)
- Design patient registry (IRB submission, REDCap setup, consent forms)
- Plan research grant program (RFA draft, review criteria, budget $100K Year 2)
- Physician education pilot (CME course outline, 50 pulmonologists trained)

**Q4: Fundraising Scale**

- Plan Year 2 gala (venue, date, committee, save-the-date‚Äîexecute Q1 Year 2)
- Major gifts (identify 50 prospects, 10 meetings, close 3 gifts $10K+)
- Year-end campaign (email, social media, $75K goal‚Äîpush to $500K total Year 1 revenue)
- Foundation grants (apply to 5 foundations‚ÄîNEA, RRF, Patient Advocate Foundation, expect 2-3 awards Year 2)

---

### FOR DONORS: How to Maximize Your Impact

**Tier 1: $100-$1,000 (Foundation Building)**

- Your gift ‚Üí operating costs (staff, IT, programs‚Äîevery dollar critical in Year 1-2)
- Consider: Monthly recurring ($25/month = $300/year‚Äîpredictable revenue, Foundation can plan)

**Tier 2: $1,000-$10,000 (Program Sponsor)**

- Your gift ‚Üí specific program (sponsor 1 patient navigator for 2 months, or 10 families' emergency assistance)
- Recognition: Patient newsletter acknowledgment, website donor list

**Tier 3: $10,000-$100,000 (Major Donor)**

- Your gift ‚Üí strategic initiatives (fund registry for 1 year, or biobank sample storage)
- Recognition: Named fund ("Smith Family Research Grant"), gala table, annual report feature
- Engagement: Quarterly ED updates, site visits, SAB meeting attendance

**Tier 4: $100,000+ (Transformational)**

- Your gift ‚Üí capital campaign (endowment, building fund [if physical location], gene therapy co-funding)
- Recognition: Building naming, endowed chair, legacy society
- Engagement: Board seat (if desired), strategic planning input, deep partnership

**Planned Giving** (Any Amount):

- Include Foundation in will (bequest), retirement account beneficiary, or life insurance
- Impact: Perpetual support‚Äîendowment generates 4-5% annual income forever
- Tax benefit: Estate tax deduction (if applicable), heirs avoid income tax on IRA

---

### FOR PATIENTS: How to Get Involved

**Just Diagnosed?**

1. Download Welcome Packet (MarkEglyFoundation.org/Welcome)
2. Schedule navigator call (1-hour, free‚Äîinsurance, treatment, next steps)
3. Join peer support group (virtual, Wednesdays 7pm ET‚Äîmeet others like you)

**Want to Help Others?**

1. Share your story (video or written‚Äîadvocacy, fundraising, awareness)
2. Volunteer (event support, peer mentor, patient advisory board)
3. Participate in registry (donate data‚Äîaccelerate research, 30 minutes online)

**Want to Advocate?**

1. Join grassroots advocacy program (train to meet Congress, tell your story)
2. Write op-ed (local newspaper‚Äî"I have AATD, here's why early diagnosis matters")
3. Social media (share Foundation content‚Äî#Alpha1 #RareDisease, amplify reach)

**Want to Fundraise?**

1. DIY event (birthday fundraiser, Facebook fundraiser, bake sale‚ÄîFoundation provides toolkit)
2. Endurance event (run marathon for AATD, recruit sponsors‚ÄîFoundation provides training support)
3. Legacy gift (include Foundation in will‚Äîultimate gift, costs nothing today)

---

## Conclusion: The Path Forward

### What Success Looks Like (10 Years)

**For Patients**:

- Diagnosed in months, not years (genetic testing, newborn screening‚Äîcatch early)
- Supported from day 1 (navigator, support group, financial help‚Äînot alone)
- Access to cutting-edge research (gene therapy trials, diagnostics‚Äîhope for cure)
- Voice heard (patient advisory board, policy advocacy‚Äîpatients lead, not just served)

**For Science**:

- World's largest AATD registry (20,000 patients, 20-year longitudinal data‚Äîirreplaceable resource)
- Dozens of funded studies (Foundation grants, pharma partnerships‚Äî$50M research investment)
- Gene therapy approved (FDA, curative treatment‚Äîpatients live normal lives)
- Diagnostic innovation (rapid test, $50, 5 minutes‚Äîprimary care doctors screen everyone)

**For the AATD Community**:

- 50% diagnosis rate (45,000 additional patients found‚Äîlives saved)
- Policy wins (newborn screening in 25 states, Medicare coverage expanded‚Äîsystemic change)
- Public awareness (AATD = known disease [like CF]‚Äînot mystery)
- Mark Egly's legacy honored (Foundation embodies his values‚Äîpatient-centered, hopeful, relentless)

---

### The Mark Egly Foundation Promise

**To Patients**: We will never give up until AATD is diagnosed early, treated effectively, and ultimately cured.

**To Families**: We will walk alongside you‚Äîfrom first diagnosis to long-term management, you are not alone.

**To Researchers**: We will provide the data, funding, and partnerships you need to make breakthroughs.

**To the Community**: We will honor Mark Egly's legacy by building the AATD foundation he envisioned‚Äîpatient-centered, science-driven, and unwavering in pursuit of a cure.

---

## Next Steps: Launch Checklist

### Immediate (Next 30 Days)

- [ ] Secure initial funding ($100K‚ÄîBoard commitments, anchor donors)
- [ ] Retain nonprofit attorney (file Articles, Bylaws, 501(c)(3))
- [ ] Recruit founding Board (7 members‚Äîdiversity in expertise, geography, demographics)
- [ ] Hire Executive Director (national search, 60-day timeline)
- [ ] Reserve Foundation name (domain MarkEglyFoundation.org, social handles)

### Short-Term (90 Days)

- [ ] 501(c)(3) application submitted (IRS Form 1023)
- [ ] Initial staff hired (ED, Program Manager, Navigator, Development Coordinator)
- [ ] Operations established (bank account, QuickBooks, insurance, workspace)
- [ ] First patient programs launched (support group, navigation, welcome packet)
- [ ] Donor database live (250 prospects loaded, first 50 donors)

### Medium-Term (6 Months)

- [ ] 501(c)(3) approval received (tax-deductible receipts issued)
- [ ] Scientific Advisory Board recruited (5 experts)
- [ ] Patient registry designed (IRB approved, consent forms ready)
- [ ] Individual giving program mature (300 donors, $300K raised)
- [ ] Education portal launched (WordPress, 50 articles, 500 monthly visitors)

### Long-Term (1 Year)

- [ ] Patient registry enrolling (target 500 participants)
- [ ] Research grant program announced (RFA, $100K awarded)
- [ ] Major fundraising event (gala, net $200K)
- [ ] Pharmaceutical partnership (1 company, $200K commitment)
- [ ] Year 1 Annual Report published (impact, financials, patient stories‚Äîtransparency, credibility)

---

**This is the roadmap. Now let's build it.**

**For Mark. For every AATD patient. For a future where AATD is history.**

---

**Document Index Complete: 89/89 Strategic Documents**

**Mark Egly Foundation**
_Breathe Easier. Live Fully. Find a Cure._

üìß Contact: info@markeglyfoundation.org
üåê Website: MarkEglyFoundation.org
üìç Location: [City, State TBD]

---

**"Mark dreamed of a day when no AATD patient would go undiagnosed, unsupported, or without hope. This Foundation is that dream, realized."**

‚Äî Founding Board of Directors

---

_Approved: [Date]_
_Reviewed Annually_
_Version: 1.0_
